Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Jeanette K Doorduijn, MD PhD, Monique C. Minnema, MD PhD, Marie Jose Kersten, MD PhD, Pieternella J Lugtenburg, MD PhD, Martin R. Schipperus, MD PhD, Marinus van Marwijk Kooy, MD PhD, Marius MacKenzie, MD PhD, Josée M Zijlstra, MD, Henriette W Berenschot, MD, M. R Schaafsma, MD PhD, Dana A Chitu, PhD, Hanneke C. Kluin-Nelemans, MD PhD

Blood (2015) 126 (23): 339.

https://doi.org/10.1182/blood.V126.23.339.339

Published: 2015

Journal Articles

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Pieter Sonneveld, MDPhD, Emilie Asselbergs, Bronno Van der Holt, PhD, Sonja Zweegman, MDPhD, Marie jose Kerstens, MD, Edo Vellenga, MD PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2014) 124 (21): 2118.

https://doi.org/10.1182/blood.V124.21.2118.2118

Published: 2014

Journal Articles

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Pieter Sonneveld, MD, Ph.D, Emilie Asselberg-Hacker, Sonja Zweegman, MD PhD, Bronno van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk Kooy, MD, PhD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2013) 122 (21): 688.

https://doi.org/10.1182/blood.V122.21.688.688

Published: 2013

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Pieter Sonneveld, MD, Emilie Asselbergs, Sonja Zweegman, MD, PhD, Bronno Van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Henk Lokhorst, MD, PhD

Blood (2012) 120 (21): 333.

https://doi.org/10.1182/blood.V120.21.333.333

Published: 2012

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

Pieter Sonneveld, MD, PhD, Emilie Hacker, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD, PhD, Edo Vellenga, PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD

Blood (2011) 118 (21): 633.

https://doi.org/10.1182/blood.V118.21.633.633

Published: 2011

Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD

Blood (2005) 106 (11): 16.

https://doi.org/10.1182/blood.V106.11.16.16

Published: 2005

NARROW

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only